FindTrial
Sign In

Retrospective evaluation of the therapeutic use of [90Y]-radiolabeled Zevalin (90yttrium-ibritumomab-tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma and for the treatment of patients with CD20-positive non-Hodgkin's lymphoma (NHL) of the B-cell type who relapsed or were refractory after treatment with rituximab.

Retrospective evaluation of the therapeutic use of [90Y]-radiolabeled Zevalin (90yttrium-ibritumomab-tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma and for the treatment of patients with CD20-positive non-Hodgkin's lymphoma (NHL) of the B-cell type who relapsed or were refractory after treatment with rituximab.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035124
Enrollment
98
Registered
2024-09-24
Start date
2023-10-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular lymphoma and relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma (NHL) of the B-cell type

Interventions

Group 1: Patients of age >18 years who have received 90Yttrium-Ibritumomab-Tiuxetan as consolidation in primary therapy after remission induction or after treatment with Rituximab for relapsed or refr

Sponsors

Klinikum Chemnitz gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with histologically confirmed follicular B-cell lymphoma who receive consolidating maintenance therapy after remission induction as part of primary therapy or patients with histologically confirmed follicular B-cell lymphoma after treatment with rituximab in relapsed or refractory disease progression

Exclusion criteria

Exclusion criteria: Patients who did not receive 90Yttrium-Ibritumomab-Tiuxetan within the approval criteria are excluded from the analysis

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS), overall survival (OS), event-free survival (EFS)—

Secondary

MeasureTime frame
Toxicity (need for hemosubstitution, grade 3-4 toxicities according to CTCAE, duration of severe neutropenia/leukocytopenia and thrombocytopenia, possible need for autologous stem cell support, development of secondary malignancies)—

Countries

Germany

Contacts

Public ContactMathias Hänel

Klinikum Chemnitz gGmbH

m.haenel@skc.de+49 371 333 44501

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026